Treatment effect sizes vary in randomized trials depending on type of outcome measure

Session: 

Oral session: Patient or healthcare consumers involvement and shared decision-making (3)

Date: 

Thursday 24 October 2019 - 11:00 to 12:30

Location: 

All authors in correct order:

Berthelsen DB1, Ginnerup-Nielsen E2, Juhl C3, Lund H4, Henriksen M5, Hróbjartsson A6, Nielsen SM2, Voshaar M7, Christensen R8
1 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Danmark
2 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
3 Research Unit of Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense and Dep. of Physiotherapy and Occupational Therapy, University Hospital of Copenhagen, Gentofte, Denmark
4 Centre for Evidence-Based Practice, Western Norway University of Applied Sciences, Bergen, Denmark
5 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen and Department of Physical and Occupational Therapy, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
6 Center for Evidence-Based Medicine, University of Southern Denmark/Odense University Hospital, Odense, Denmark
7 Department of Psychology, Health and Technology, University of Twente, Enschede, The Nederlands
8 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark
Presenting author and contact person

Presenting author:

Hans Lund

Contact person:

Abstract text
Background: Patient-Reported Outcome Measures (PROMs) yield insightful information when assessing treatment effect in clinical practice; however, they may overestimate effects, particularly in non-pharmacological studies.

Objectives: to compare estimated treatment effects of physical therapy (PT) between PROMs and outcomes measured in other ways.

Methods: we selected randomized trials of PT with both a PROM and a non-PROM included in Cochrane Systematic Reviews (CSRs). Two review authors independently extracted data and 'Rsk of bias' assessments. Our primary outcome was the ratio of odds ratios (ROR), used to quantify how effects vary between PROMs and non-PROMs; an ROR greater than 1 indicates larger effect when assessed by PROMs. We used REML methods to estimate associations of trial characteristics with effects and between-trial heterogeneity.

Results: from 90 relevant CSRs, we included 205 PT trials. The summary ROR across all the comparisons was not statistically significant (ROR 0.88, 95% confidence interval (CI) 0.70 to 1.12; P = 0.30); however, the heterogeneity was substantial (I2 = 88.1%). When stratifying non-PROMs further into clearly objective non-PROMs (e.g. biomarkers) and other non-PROMs (e.g. aerobic capacity), the PROMs appeared more favourable than did clearly objective non-PROMs (ROR 1.92, 95% CI 0.99 to 3.72; P = 0.05). On the contrary, patients’ own report of treatment effects appeared less favourable when compared to less objective non-PROMs (ROR 0.80, 95% CI 0.62 to 1.02; P = 0.07). When outcomes reflected the same construct, PROMs appeared less favourable than comparable non-PROMs (ROR 0.29, 95% CI 0.15 to 0.55; P < 0.001).

Conclusions: estimated treatment effects based on PROMs are generally comparable to treatment effects measured in other ways. However, in our study, PROMs indicate a more favourable treatment effect compared to treatment effects based on clearly objective outcomes, and a less favourable treatment effect when compared to less objective non-PROMs. Likewise, PROMs indicated a less favourable treatment effect when outcomes were based on the same construct. Patients' and clinicians' different perspectives on a disease may influence estimates of treatment effects in randomized trials, and including other instruments/measures together with PROMs should be considered in clinical practice and when developing core outcome measurement sets in various conditions.

Patient or healthcare consumer involvement: three patient research partners (PRPs) were involved in designing the study and discussing the results. During protocol development, the PRPs participated in discussions of relevance, content, and ethics. Each PRP wrote a hypothesis of expected results, and all these three hypotheses were in agreement with the original hypothesis. During subsequent discussions of results, the PRPs gave their perspective on findings based on their experiences of pros and cons when assessing treatment effects using PROMs and other measurements respectively.